A review on viral keratitis caused by
herpes simplex virus. J Sci.
Cohen, "New onset of
herpes simplex virus epithelial keratitis after penetrating keratoplasty," American Journal of Ophthalmology, vol.
Trends in seroprevalence of
herpes simplex virus type 2 among non-Hispanic blacks and non-Hispanic whites aged 14 to 49 years-United States, 1988 to 2010.
Lausch, "Protective antibody therapy is associated with reduced chemokine transcripts in
herpes simplex virus type 1 corneal infection," Journal of Virology, vol.
Levy, "Successful treatment of progressive acyclovir-resistant
herpes simplex virus using intravenous foscarnet in a patient with the acquired immunodeficiency syndrome," Archives of Dermatology, vol.
[1.] Grunewald K, Desai P, Winkler DC (2003) Three-Dimensional Structure of
Herpes Simplex Virus from Cryo-Electron Tomography.
The report provides comprehensive information on the therapeutics under development for
Herpes Simplex Virus (HSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
This review will focus on the two main contenders, adenovirus and
herpes simplex virus, for glioma treatment and discuss how far the field has come since its conception.
The
herpes simplex virus, HSV-1, is responsible, but in rare cases, they can also be caused by the type 2 virus (HSV-2), when someone with genital herpes has oral sex.
As viral resistance to available chemical drugs and virus latency duration leads to worries in
herpes simplex virus type 1 and 2 infections treatment, there are growing need for new anti-herpes treatments.
Herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) are double-stranded DNA viruses and are members of the Herpesviridae family.
Herpes simplex virus (HSV) types one and two (HSV-1 and HSV-2) are the main cause of genital herpes, which is the main cause of genital ulcers worldwide.